Of note, in vivo data showed that STAT3 knockdown reversed this resistance, implying that STAT3-targeting, together with immune checkpoint inhibitors, is a viable pharmacological strategy that can overcome resistance to immunotherapy in NSCLC [72]. The gene discussed is STAT3; the disease is non-small cell lung carcinoma.